GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (FRA:2VSA) » Definitions » Cyclically Adjusted Price-to-FCF

Verastem (FRA:2VSA) Cyclically Adjusted Price-to-FCF : (As of Sep. 23, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Verastem Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Verastem Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Verastem's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Cyclically Adjusted Price-to-FCF Chart

Verastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Verastem Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Verastem's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Verastem's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verastem's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Verastem's Cyclically Adjusted Price-to-FCF falls into.



Verastem Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Verastem's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Verastem's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.954/132.5538*132.5538
=-0.954

Current CPI (Jun. 2024) = 132.5538.

Verastem Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -3.862 100.428 -5.097
201412 -3.789 99.070 -5.070
201503 -3.967 99.621 -5.278
201506 -3.519 100.684 -4.633
201509 -3.367 100.392 -4.446
201512 -3.044 99.792 -4.043
201603 -3.154 100.470 -4.161
201606 -1.932 101.688 -2.518
201609 -1.740 101.861 -2.264
201612 -1.830 101.863 -2.381
201703 -3.231 102.862 -4.164
201706 -4.180 103.349 -5.361
201709 -3.170 104.136 -4.035
201712 -4.899 104.011 -6.243
201803 -4.318 105.290 -5.436
201806 -1.826 106.317 -2.277
201809 -3.230 106.507 -4.020
201812 -4.789 105.998 -5.989
201903 -5.577 107.251 -6.893
201906 -4.984 108.070 -6.113
201909 -4.088 108.329 -5.002
201912 -5.265 108.420 -6.437
202003 -3.414 108.902 -4.155
202006 -1.453 108.767 -1.771
202009 2.685 109.815 3.241
202012 -1.259 109.897 -1.519
202103 -1.146 111.754 -1.359
202106 -0.777 114.631 -0.898
202109 -0.614 115.734 -0.703
202112 -0.606 117.630 -0.683
202203 -1.128 121.301 -1.233
202206 -0.773 125.017 -0.820
202209 -0.927 125.227 -0.981
202212 -0.920 125.222 -0.974
202303 -1.133 127.348 -1.179
202306 -1.036 128.729 -1.067
202309 -0.580 129.860 -0.592
202312 -1.013 129.419 -1.038
202403 -0.971 131.776 -0.977
202406 -0.954 132.554 -0.954

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Verastem  (FRA:2VSA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Verastem Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Verastem's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem Business Description

Industry
Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem Headlines

No Headlines